Welcome to our dedicated page for BlackRock Capital Allocation Term Trust SEC filings (Ticker: BCAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BlackRock Capital Allocation Term Trust's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BlackRock Capital Allocation Term Trust's regulatory disclosures and financial reporting.
BlackRock Capital Allocation Term Trust identifies Charles Park as its Chief Compliance Officer in an insider ownership filing. Remarks state he previously served as Chief Compliance Officer from September 24, 2020 to June 30, 2023 and was reappointed to the role effective August 1, 2026. No securities holdings or insider transactions are reported in this submission.
BlackRock Capital Allocation Term Trust portfolio manager Richard M. Rieder reported an open-market sale of 35,734 shares of Common Stock on 2026-07-13 at an average price of $15.9601 per share. Following this transaction, he directly owns 272,353 shares of the trust.
BlackRock Capital Allocation Term Trust (BCAT) and affiliated BlackRock ESG Capital Allocation Term Trust (ECAT) filed their Form N-CSR shareholder report for the fiscal period ended 12/31/2025, presenting audited financials, portfolio holdings, performance and distribution breakdowns. The filing discloses each Trust’s managed distribution plan and distribution amounts per share.
The excerpt shows BCAT’s total cumulative distributions for the fiscal period were $3.321040 per share (of which $0.338464 was net income and $2.982576 was return of capital) and ECAT’s total cumulative distributions were $3.537140 per share (including $0.219986 net income and $3.292798 return of capital). The Board-set fixed monthly amounts are $0.00 for BCAT and $0.278540 for ECAT.
BlackRock Capital Allocation Term Trust portfolio manager Sarah Croughan Thompson reported insider transactions involving common stock and phantom shares. On January 30, 2026, 693.8508 phantom shares were converted into 693.8508 common shares at an exercise price of $0.00 and then sold at $14.70 per share, leaving zero common shares directly held.
After these moves, Thompson continues to hold 1,387.7016 phantom shares, which are cash-settled instruments economically equivalent to common stock. According to the disclosure, these phantom shares were granted on January 31, 2025 and vest in three equal annual installments, becoming payable in cash as they vest.
BlackRock Capital Allocation Term Trust portfolio manager Koesterich Russell Jared reported multiple transactions dated January 30, 2026. He exercised 5,554.0398 shares of common stock and then disposed of 5,554.0398 shares at $14.7 per share, leaving 33,000 common shares held directly.
He also settled phantom share awards tied to prior grants. One block of 3,414.0154 phantom shares and another of 2,140.0245 phantom shares, each economically equivalent to common stock, were moved, leaving 6,828.0307 and 2,140.0245 phantom shares, respectively. Phantom shares are payable in cash as they vest in three annual installments from the January 31, 2024 and January 31, 2025 grant dates.
BlackRock Capital Allocation Term Trust portfolio manager Randy William Berkowitz reported an insider stock sale. On January 30, 2026, he acquired 3,680.3862 shares of common stock at a transaction price of $0.00 per share and then sold the same 3,680.3862 shares at $14.70 per share, leaving no common shares directly owned after the transactions.
Separately, he reported activity in phantom shares, which are stated to be the economic equivalent of common stock and payable in cash on vesting. Transactions covered 712.1738 and 2,968.2123 phantom shares tied to prior grants from January 31, 2024 and January 31, 2025.
Saba Capital Management, L.P., Saba Capital Management GP, LLC and Boaz R. Weinstein jointly filed Amendment No. 21 to their Schedule 13D on BlackRock Capital Allocation Term Trust (ticker BCAT).
- Ownership disclosed: 5,352,474 – 5,352,475 common shares, equal to 5.11 % of the 104,775,271 shares outstanding as of 5/19/25.
- Voting/Dispositive power: 0 sole; full power is shared among the reporting persons.
- Cost basis: approximately $78.4 million in aggregate consideration, funded with investor capital and ordinary-course margin borrowings.
- Transaction window: open-market purchases between 7/14/25 and 7/24/25 prompted the filing.
- Purpose of transaction: “Not Applicable”; no specific strategic intentions or agreements were disclosed (Items 4 & 6).
The filing converts the group from passive (13G) to active (13D) status and updates Items 3, 5 and 7. No criminal or civil proceedings are reported against the filers, and signature authority is provided by General Counsel Michael D’Angelo.